Literature DB >> 17686554

Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice.

Maria Victoria Delpino1, Silvia Marcela Estein, Carlos Alberto Fossati, Pablo César Baldi, Juliana Cassataro.   

Abstract

The immunogenicity and protective efficacy of recombinant SurA (rSurA) and rDnaK from Brucella spp. were evaluated in BALB/c mice. Immunization with rSurA in adjuvant induced a vigorous immunoglobulin G (IgG) response, with higher IgG2a than IgG1 titers. In addition, after in vitro stimulation with rSurA, spleen cells from rSurA-immunized mice produced interleukin-2 (IL-2), interferon (IFN)-gamma, IL-4 and IL-5. Immunization with rDnaK plus adjuvant induced a strong humoral response resulting in similar anti-rDnaK IgG titers than immunization with rDnaK alone. IgG2a titers predominated over IgG1 in mice injected with rDnaK alone or rDnaK plus adjuvant. Spleen cells from mice immunized with rDnaK plus adjuvant secreted IFN-gamma and IL-2 upon stimulation with rDnaK and induced a specific cytotoxic response. On the contrary, mice immunized with rDnaK alone did not exhibit a specific T helper or cytotoxic response in vitro. Mice given rSurA or rDnaK with adjuvant exhibited a significant degree of protection whereas immunization with rDnaK alone induced a low but still statistically significant level of protection against B. abortus infection. All studied vaccines were less protected than mice immunized with H38 or B. abortus strain 19 control vaccines. Altogether these results suggest that rSurA or rDnaK induce partial protection against B. abortus infection and could be useful candidates for the development of subunit vaccines against brucellosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686554     DOI: 10.1016/j.vaccine.2007.07.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.

Authors:  Neeta Jain-Gupta; Araceli Contreras-Rodriguez; Ramesh Vemulapalli; Sharon G Witonsky; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  FEMS Immunol Med Microbiol       Date:  2012-12

2.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.

Authors:  Dina Moustafa; Virendra K Garg; Neeta Jain; Nammalwar Sriranganathan; Ramesh Vemulapalli
Journal:  Vaccine       Date:  2010-11-23       Impact factor: 3.641

4.  Immunization with Brucella VirB proteins reduces organ colonization in mice through a Th1-type immune response and elicits a similar immune response in dogs.

Authors:  Cora N Pollak; María Magdalena Wanke; Silvia M Estein; M Victoria Delpino; Norma E Monachesi; Elida A Comercio; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

5.  Sustained and differential antibody responses to virulence proteins of Brucella melitensis during acute and chronic infections in human brucellosis.

Authors:  J Xu; Y Qiu; M Cui; Y Ke; Q Zhen; X Yuan; Y Yu; X Du; J Yuan; H Song; Z Wang; G Gao; S Yu; Y Wang; L Huang; Z Chen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-15       Impact factor: 3.267

6.  Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.

Authors:  Karina A Pasquevich; Silvia M Estein; Clara García Samartino; Clara García Samartino; Astrid Zwerdling; Lorena M Coria; Paula Barrionuevo; Carlos A Fossati; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

7.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

8.  Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development.

Authors:  Samantha Sayers; Guerlain Ulysse; Zuoshuang Xiang; Yongqun He
Journal:  J Biomed Biotechnol       Date:  2012-03-13

9.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06

Review 10.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.